MDM2 overexpression is rare in ovarian carcinoma irrespective of TP53 mutation status
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Somatic mutations in TP53 are seen in many human cancers. In addition, the protein product of the wild-type TP53 can be sequestered by the protein MDM2 (murine double minute 2). This protein is commonly overexpressed in human sarcomas and gliomas, usually as a result of gene amplification. In this study, 43 ovarian carcinomas (OCs) were analysed for aberrations in the TP53 gene by immunohistochemistry (IHC), loss of heterozygosity (LOH) or mutation analysis. The MDM2 gene and its product was studied by Southern blotting and IHC. Over 50% of the OCs studied showed mutations in TP53 by either direct sequencing (19/36, 53%), positive IHC (23,43, 53%) or both, whereas 0/32 had amplification of MDM2 and only 1/37 tumours had positive IHC using the anti-MDM2 antibody IF-2. The solitary example of positive IHC in this series was seen in a mixed müllerian tumour with sarcomatous differentiation and was not accompanied by MDM2 DNA amplification. These results support previous data showing that around 50% of OCs have mutations in TP53 and in addition, suggest that MDM2 is not amplified in OC, but the presence of sarcomatous features in mixed müllerian tumours may result in positive immunohistochemistry with IF-2.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Amplification of a gene encoding a p53-associated protein in human sarcomas
Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., & Vogelstein, B. (1992) · Nature · doi:10.1038/358080a0 · Cited by 1,949
Cited by
The MDM2 gene amplification database
Momand, J. (1998) · Nucleic Acids Research · doi:10.1093/nar/26.15.3453 · Cited by 982
Rayburn, E., Zhang, R., He, J., & Wang, H. (2005) · Current Cancer Drug Targets · doi:10.2174/1568009053332636 · Cited by 265
“…No correlation 46 [179] Ovarian 12%-41% No correlation 90 [180] Ovarian 13% No correlation 347 [181] Ovarian 3% n/a 43 [182] Ovarian Positive n/a 10 [183] Bladder 18% n/a 88 [45] Bladder positive Worse 80 [77] Bladder 20% no correlation 50 [44] Bladder 18%-49% no correlation 92 [43] Bladder 38%…”
BackgroundThe Role of MDM2 Amplification and Overexpression in Tumorigenesis
Oliner, J. D., Saiki, A. Y., & Caenepeel, S. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026336 · Cited by 246
“…malignant glioma (Reifenberger et al. 1993), breast carcinoma (Quesnel et al. 1994; McCann et al. 1995; Choschzick et al. 2010), ovarian carcinoma (Foulkes et al. 1995; Courjal et al. 1996; Mayr et al. 2006), urothelial carcinoma (Habuchi et al. 1994; Lianes et al. 1994), lung carcinoma…”
Overholtzer, M., Rao, P. H., Favis, R., Lu, X.-Y., Elowitz, M. B., Barany, F., Ladanyi, M., Gorlick, R., & Levine, A. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1934852100 · Cited by 193
Metadata
- Authors
- Foulkes, W., Stamp, G., Afzal, S., Lalani, N., McFarlane, C., Trowsdale, J., & Campbell, I.
- Venue
- British Journal of Cancer
- Published
- 1995-10
- Volume
- 72
- Issue
- 4
- Pages
- 883-888
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2021432159
- Cited by
- 39
- References
- 1
- FWCI
- 1.77
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: MDM2 overexpression is rare in ovarian carcinoma irrespective of TP53 mutation status. https://app.cochat.ai/papers/10.1038/bjc.1995.428
- The paper
- Foulkes, W., Stamp, G., Afzal, S., Lalani, N., McFarlane, C., Trowsdale, J., & Campbell, I. (1995). MDM2 overexpression is rare in ovarian carcinoma irrespective of TP53 mutation status. British Journal of Cancer. https://doi.org/10.1038/bjc.1995.428
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.